Vaxcyte, Inc.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Tuesday, shares of Vaxcyte Inc (Symbol: PCVX) entered into oversold territory, hitting an RSI reading of 29.5, after changing hands as low as $34.32 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 61.8. A bullish investor could look at PCVX's 29.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of PCVX shares:
Looking at the chart above, PCVX's low point in its 52 week range is $17.44 per share, with $49.31 as the 52 week high point — that compares with a last trade of $34.47.
Past Earnings
GROM Split History
EAA Historical Stock Prices
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte Becomes Oversold (PCVX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Tuesday, shares of Vaxcyte Inc (Symbol: PCVX) entered into oversold territory, hitting an RSI reading of 26.0, after changing hands as low as $29.225 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 54.8. A bullish investor could look at PCVX's 26.0 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of PCVX shares:
Looking at the chart above, PCVX's low point in its 52 week range is $27.66 per share, with $121.055 as the 52 week high point — that compares with a last trade of $29.24.
Find out what 9 other oversold stocks you need to know about »
Also see:
Kenvue RSI
Funds Holding KLMN
INV YTD Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Oversold Conditions For Vaxcyte (PCVX)

Investors eyeing a purchase of Vaxcyte Inc (Symbol: PCVX) shares, but cautious about paying the going market price of $31.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $20 strike, which has a bid at the time of this writing of $1.95. Collecting that bid as the premium represents a 9.8% return against the $20 commitment, or a 14.7% annualized rate of return (at Stock Options Channel we call this the YieldBoost).
Selling a put does not give an investor access to PCVX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $20 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Vaxcyte Inc sees its shares decline 35.7% and the contract is exercised (resulting in a cost basis of $18.05 per share before broker commissions, subtracting the $1.95 from $20), the only upside to the put seller is from collecting that premium for the 14.7% annualized rate of return.
Below is a chart showing the trailing twelve month trading history for Vaxcyte Inc, and highlighting in green where the $20 strike is located relative to that history:
The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the December put at the $20 strike for the 14.7% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Vaxcyte Inc (considering the last 249 trading day closing values as well as today's price of $31.11) to be 83%. For other put options contract ideas at the various different available expirations, visit the PCVX Stock Options page of StockOptionsChannel.com.
In mid-afternoon trading on Monday, the put volume among S&P 500 components was 961,483 contracts, with call volume at 1.13M, for a put:call ratio of 0.85 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers. Find out which 15 call and put options traders are talking about today.
Also see:
Socially Responsible Preferreds
PME shares outstanding history
Institutional Holders of BLNK
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Commit To Buy Vaxcyte At $20, Earn 14.7% Annualized Using Options

Vaxcyte PCVX is a clinical-stage biotech focused on developing vaccines to prevent or treat bacterial infectious diseases.
In the past month, PCVX's shares have nosedived 56%. This downside came after Vaxcyte reported mixed results from a phase II study on its investigational pneumococcal conjugate vaccine (PCV) in healthy infants.
Adding to this headwind, the broader biotech/drug sector is feeling the pressure from the resignation of a senior FDA official instrumental in driving biotech innovation, which has raised alarms around the agency’s ability to maintain momentum on innovation and regulatory clarity.
PCVX Stock’s Performance
Vaxcyte’s shares have plummeted more than 62% year to date compared with the industry’s 8% decline, as seen in the chart below. During this timeframe, the stock has also underperformed the broader Medical sector and the S&P 500 Index. The company’s shares are also trading below its 50 and 200-day moving averages.
PCVX Stock Underperforms Industry, Sector & S&P 500
More on PCVX’s Pneumococcal Vaccine Study Results
Last week, Vaxcyte reported top-line results from the mid-stage study that evaluated its 24-valent PCV VAX-24 against Pfizer’s PFE Prevnar 20. The Pfizer vaccine is approved for preventing invasive pneumococcal disease (IPD) caused by 20 serotypes, all of which are included in the Vaxcyte vaccine, along with four additional ones.
Data from this dose-finding study showed that the mid-dose of VAX-24 met the non-inferiority criteria for seroconversion and showed robust immune responses across all serotypes, particularly for the highest circulating ones. However, the vaccine did not meet the non-inferiority criteria for four of the 24 serotypes compared with Pfizer’s Prevnar 20. This mixed result was a major reason behind the decline in PCVX's share price.
Additionally, VAX-24 was well-tolerated and demonstrated a safety and tolerability profile similar to Pfizer’s Prevnar 20. The mid-dose of VAX-24 also met the target IgG Geometric Mean Ratio and generated strong opsonophagocytic assay responses, which are considered key markers for protection against IPD.
Based on these results, Vaxcyte has selected the mid-dose formulation of VAX-24 for potential advancement into late-stage development. Depending on the top-line results from the ongoing mid-stage study on its investigational 31-valent PCV vaccine VAX-31 in infants, expected in mid-2026, the company plans to start a phase III study in infants with either VAX-24 or VAX-31.
Vaxcyte intends to report full post-dose 4 booster data for VAX-24 by the end of this year.
PCVX’s Zacks Rank
Vaxcyte currently carries a Zacks Rank #3 (Hold).
Vaxcyte, Inc.
Vaxcyte, Inc. | Vaxcyte, Inc. Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are ANI Pharmaceuticals ANIP and 89bio ETNB. While ANIP currently sports a Zacks Rank #1 (Strong Buy), ETNB carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $5.54 to $6.35. EPS estimates for 2026 have increased from $6.75 to $7.21 during the same period.
ANI Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 17.32%.
Estimates for 89bio’s loss per share have narrowed from $2.51 to $1.98 for 2025 in the past 60 days. During the same time frame, estimates for 2026 loss per share have improved from $2.94 to $2.15.
89bio’s earnings missed estimates in three of the trailing four quarters and beat the mark on one occasion, delivering an average negative surprise of 46.18%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pfizer Inc. (PFE) : Free Stock Analysis Report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
89BIO (ETNB) : Free Stock Analysis Report
Vaxcyte, Inc. (PCVX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Vaxcyte Stock Plummets 56% in a Month: Here's the Reason

Shares of popular vaccine and gene therapy makers took a beating on Monday following the resignation of a key FDA official, Dr. Peter Marks.
Why Did Peter Marks Quit?
In his resignation letter posted by the New York Times, Marks called out the newly appointed Health and Human Services (“HHS”) Secretary Robert F. Kennedy Jr. — a well-known vaccine skeptic — for promoting ‘misinformation and lies’ about the safety of FDA-approved vaccines.
Marks expressed strong concerns about efforts to undermine vaccine safety. He warned about the rising hesitancy toward vaccines and their consequences, citing the recent measles outbreak as an example of what happens when trust in vaccines is eroded.
Per some third-party reports, Marks’ decision came after he was given a choice to either resign or face termination.
Stocks That Fell Following the News
Following the above announcement, vaccine makers were significantly affected by the news. Shares of Moderna MRNA were down about 9% on Monday while those of Novavax NVAX lost over 8%. Moderna and Novavax are among the handful of companies that market a COVID-19 vaccine.
Among vaccine stocks, clinical-stage biotech Vaxcyte PCVX suffered the largest decline, with its shares plummeting nearly 46%. The fall in PCVX shares was further amplified by mixed results from a mid-stage study on its pneumococcal vaccine in infants.
Stocks in the gene therapy space were also negatively impacted. Shares of Sarepta Therapeutics SRPT lost more than 9% while those of CRISPR Therapeutics CRSP declined 8%. Both companies have an FDA-approved gene therapy in their portfolio. Sarepta markets Elevidys for a rare genetic disorder called Duchenne muscular dystrophy, while CRISPR’s Casgevy is approved for sickle cell disease and thalassemia.
Why is the Market Concerned About Marks’ Exit?
Dr. Marks, who headed the FDA’s Center for Biologics Evaluation and Research (“CBER”), has been a strong advocate for faster approval of vaccines and gene therapies. During his tenure, he was responsible for approving 22 gene therapies and played a major role in Operation Warp Speed, the initiative that accelerated the development of the COVID-19 vaccine.
The departure of a leading authority like Peter Marks, who has been a driving force behind regulatory efficiency in biotech innovation, has sparked concerns about the future pace of critical drug approvals. As a key figure in overseeing the rollout of COVID-19 vaccines and shaping regulatory pathways for cell and gene therapies, his exit raises questions about the FDA’s ability to maintain its momentum in advancing innovative treatments.
Some Wall Street analysts worry that his absence could weaken the FDA’s role in ensuring timely access to safe and effective therapies, potentially adding to the challenges already facing the biotech sector.
Zacks Rank
CRISPR Therapeutics, Moderna, Novavax, Sarepta Therapeutics and Vaxcyte carry a Zacks Rank #3 (Hold) each at present.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
Vaxcyte, Inc. (PCVX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Vaxcyte Inc (Symbol: PCVX), where a total volume of 7,810 contracts has been traded thus far today, a contract volume which is representative of approximately 781,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 70.5% of PCVX's average daily trading volume over the past month, of 1.1 million shares. Particularly high volume was seen for the $35 strike call option expiring October 17, 2025, with 5,077 contracts trading so far today, representing approximately 507,700 underlying shares of PCVX. Below is a chart showing PCVX's trailing twelve month trading history, with the $35 strike highlighted in orange:
Spectrum Brands Holdings Inc (Symbol: SPB) options are showing a volume of 2,789 contracts thus far today. That number of contracts represents approximately 278,900 underlying shares, working out to a sizeable 69.3% of SPB's average daily trading volume over the past month, of 402,355 shares. Especially high volume was seen for the $85 strike call option expiring October 17, 2025, with 1,998 contracts trading so far today, representing approximately 199,800 underlying shares of SPB. Below is a chart showing SPB's trailing twelve month trading history, with the $85 strike highlighted in orange:
And Core Scientific Inc (Symbol: CORZ) options are showing a volume of 155,486 contracts thus far today. That number of contracts represents approximately 15.5 million underlying shares, working out to a sizeable 68.5% of CORZ's average daily trading volume over the past month, of 22.7 million shares. Especially high volume was seen for the $22 strike call option expiring January 16, 2026, with 54,029 contracts trading so far today, representing approximately 5.4 million underlying shares of CORZ. Below is a chart showing CORZ's trailing twelve month trading history, with the $22 strike highlighted in orange:
For the various different available expirations for PCVX options, SPB options, or CORZ options, visit StockOptionsChannel.com.
Also see:
UMAC Past Earnings
Funds Holding HD
Institutional Holders of MKTW
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Monday Option Activity: PCVX, SPB, CORZ

In trading on Monday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 1.9% on the day. Components of that ETF showing particular strength include shares of Corcept Therapeutics, up about 83.2% and shares of Amgen, up about 2% on the day.
And underperforming other ETFs today is the SPDR S&P Biotech ETF, off about 4.4% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Vaxcyte, lower by about 50.5%, and shares of Capricor Therapeutics, lower by about 18.3% on the day.
VIDEO: Monday's ETF Movers: FBT, XBI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Monday's ETF Movers: FBT, XBI

In trading on Monday, biotechnology shares were relative laggards, down on the day by about 4.9%. Helping drag down the group were shares of Vaxcyte, down about 50.5% and shares of Taysha Gene Therapies off about 27.2% on the day.
Also lagging the market Monday are airlines shares, down on the day by about 3% as a group, led down by Surf Air Mobility, trading lower by about 19.5% and Frontier Group Holdings, trading lower by about 11.3%.
VIDEO: Monday Sector Laggards: Biotechnology, Airlines
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Monday Sector Laggards: Biotechnology, Airlines

Last November, Fundstrat analyst Tom Lee told CNBC that small-cap stocks are headed for a prolonged period of outperformance compared to the large-cap S&P 500 (SNPINDEX: ^GSPC). "I think small caps could, in the next couple of years, outperform by more than 100%," Lee said.
The opposite has actually happened since he made that prediction. The Russell 2000, a benchmark for small-cap stocks, has tumbled 16%, while the S&P 500 has declined only 8%. However, the investment thesis Lee outlined late last year remains compelling.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Here's what investors should know.
The bull case for small-cap stocks in the current market environment
The small-cap Russell 2000 achieved a total return of 7% in the last three years, dramatically underperforming the 40% return in the large-cap S&P 500. But Tom Lee thinks that trend could reverse in the years ahead as small-cap stocks benefit from lower interest rates and more attractive valuations.
The Federal Reserve began lowering its benchmark interest rate in September. That should asymmetrically benefit small-cap companies because they have more floating-rate debt. Indeed, the Russell 2000 returned an average of 45% during the 12-month period following the last five rate-cut cycles, while the S&P 500 returned an average 33%, according to Goldman Sachs.
The Russell 2000 trades at 16 times earnings, and earnings are forecast to grow at 11.5% annually in the next few years, according to Morningstar. Those figures give a price/earnings-to-growth ratio (PEG) of 1.4. Meanwhile, the S&P 500 trades at 22 times earnings, and earnings are forecast to grow at 9.4% annually in the next few years. Those numbers give a less attractive PEG of 2.3.
Lastly, Russell 2000 companies derive one-fifth of sales from outside the U.S., while S&P 500 companies derive one-half of sales from outside the U.S. Because small-cap companies are less dependent on international revenue, they are less sensitive to retaliatory tariffs that may be levied on U.S. exports. It also means they are less sensitive to a stronger U.S. dollar, which may be a consequence of the U.S. imposing tariffs on imported goods.
The Vanguard Russell 2000 ETF provides exposure to small-cap stocks
The Russell 2000 tracks about 2,000 small-cap companies that cover about 5% of U.S. stocks by market value.
The index includes companies from all 11 market sectors, but it leans most heavily toward the industrial (19%), financial (19%), and healthcare (17%) sectors. Comparatively, the S&P 500 is weighted heavily toward the information technology (31%), financial (14%), and consumer discretionary (11%) sectors.
The Vanguard Russell 2000 ETF (NASDAQ: VTWO) provides investors with exposure to the Russell 2000. The five largest holdings in the index fund are listed by weight below:
Sprouts Farmers Market: 0.6%
Insmed: 0.5%
Vaxcyte: 0.4%
SouthState: 0.4%
FTAI Aviation: 0.4%
The Vanguard Russell 2000 ETF has an expense ratio of 0.07%, which means shareholders will pay $0.70 annually on every $1,000 invested in the fund. The expense ratio on similar funds is 0.98%, according to Vanguard.
Here's the bottom line: Recent interest rate cuts, relatively cheap valuations, and the trade war initiated by the Trump administration could lead to small-cap outperformance in the years ahead. The Vanguard Russell 2000 ETF is a sensible way for investors to position their portfolios for that possible outcome.
However, investors should bear in mind that large-cap stocks have crushed small-cap stocks in recent history. So, I would personally keep my position in the Vanguard Russell 2000 ETF relatively small. And I certainly would not abandon any high-conviction large-cap stocks, nor would I abandon my S&P 500 index fund.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 803% — a market-crushing outperformance compared to 160% for the S&P 500.*
They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of March 14, 2025
Trevor Jennewine has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs Group. The Motley Fool recommends Sprouts Farmers Market. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst

Jim Wassil, the CHIEF OPERATING OFFICER of $PCVX, sold 2,085 shares of the company on 03-03-2025 for an estimated $153,950. We received data on the trade from a recent SEC filing. This was a sale of approximately 1.3% of their shares of this class of stock. Following this trade, they now own 154,931 shares of this class of $PCVX stock.
$PCVX Insider Trading Activity
$PCVX insiders have traded $PCVX stock on the open market 125 times in the past 6 months. Of those trades, 0 have been purchases and 125 have been sales.
Here’s a breakdown of recent trading of $PCVX stock by insiders over the last 6 months:
GRANT PICKERING (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 35 sales selling 96,830 shares for an estimated $10,512,110.
ANDREW GUGGENHIME (PRESIDENT AND CFO) has made 0 purchases and 17 sales selling 82,000 shares for an estimated $8,533,748.
JIM WASSIL (CHIEF OPERATING OFFICER) has made 0 purchases and 30 sales selling 68,000 shares for an estimated $6,732,333.
MIKHAIL EYDELMAN (SVP, GEN COUNSEL & CORP SEC) has made 0 purchases and 30 sales selling 32,167 shares for an estimated $3,229,055.
TERI LOXAM has made 0 purchases and 12 sales selling 12,500 shares for an estimated $1,258,693.
ELVIA COWAN (SVP, FINANCE) sold 5,000 shares for an estimated $538,350
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$PCVX Hedge Fund Activity
We have seen 194 institutional investors add shares of $PCVX stock to their portfolio, and 164 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
FMR LLC removed 2,709,019 shares (-17.1%) from their portfolio in Q4 2024, for an estimated $221,760,295
DARWIN GLOBAL MANAGEMENT, LTD. removed 2,198,187 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $179,943,587
GOLDMAN SACHS GROUP INC added 2,180,353 shares (+229.7%) to their portfolio in Q4 2024, for an estimated $178,483,696
CAPITAL RESEARCH GLOBAL INVESTORS added 1,312,302 shares (+26.8%) to their portfolio in Q4 2024, for an estimated $107,425,041
KYNAM CAPITAL MANAGEMENT, LP added 1,297,508 shares (+124.8%) to their portfolio in Q4 2024, for an estimated $106,214,004
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,193,111 shares (-29.4%) from their portfolio in Q4 2024, for an estimated $97,668,066
STATE STREET CORP added 1,133,663 shares (+33.3%) to their portfolio in Q4 2024, for an estimated $92,801,653
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.